75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Supplemental Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Partnerships link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Organization and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Supplemental Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Organization and Significant Accounting Policies - Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Fair Value of Financial Instruments - Summary of Assets that Require Fair Value Measurements on Recurring Basis and Their Respective Input Levels Based on Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Supplemental Balance Sheet Details - Schedule of Company's Short-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Supplemental Balance Sheet Details - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Supplemental Balance Sheet Details - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Acquisition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Acquisition - Summary of Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Notes Payable - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Notes Payable - Schedule of Aggregate Carrying Amounts of Term Loans (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Notes Payable - Schedule of Future Maturities of Term Loans, Including Final Payment Fee (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Notes Payable - Schedule of Future Maturities of Term Loans, Including Final Payment Fee (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Segment Reporting - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Stockholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Stockholders' Equity - Summary of Total Non-cash Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Stockholders' Equity - Summary of Total Non-cash Stock-based Compensation Expense (Details) [Default] link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Related Party Transactions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Related Party Transaction [Table] Anti-dilutive shares: Earnings Per Share, Diluted, Other Disclosure [Abstract] Common Stock, Capital Shares Reserved for Future Issuance Total common stock reserved for future issuance Number of shares available for issuance Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Rule 10B51 Arr Modified Flag Rule 10B51 arr modified flag. Business Combination, Consideration Transferred, Equity Interest, Type [Domain] Unaccreted liability for final payment fee. Unaccreted Liability For Final Payment Fee Unaccreted balance for Final Payment fee on Term Loans Long-term Line of Credit, Total Long-Term Line of Credit Borrowings under loan agreement Debt Instrument, Basis Spread on Variable Rate Debt instrument, basis spread on variable rate Commitments and Contingencies Commitments and contingencies Weighted-average number of common shares outstanding, diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Investor [Member] APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Minimum [Member] Minimum Private Placement [Member] Private Placement Private Placement of Equity Securities Debt Instrument, Interest Rate, Effective Percentage Debt instrument, interest rate, effective percentage Summary of Purchase Price Allocation Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Issued Biocon chemistry manufacturing and controls services. Biocon Chemistry Manufacturing And Controls Services Biocon and its subsidiaries chemistry, manufacturing and controls services - related party Income tax expense Income tax expense Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Related Party Transaction [Line Items] Lenders warrants exercisable for shares Shares upon exercise of warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Line of Credit Facility, Maximum Borrowing Capacity Borrowing capacity under loan agreement Cash Acquired from Acquisition Cash acquired in Bioniz acquisition Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Common stock or pre-funded warrants subject to milestone closing Common stock or pre-funded warrants subject to milestone closing [Member] Common stock or pre-funded warrants subject to milestone closing [Member] Subsequent Event Type [Domain] Biocon Biocon [Member] Biocon. Collaboration and license agreement. Collaboration And License Agreement [Abstract] Term B Loan. Term B Loan [Member] Term B Loan Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] General and Administrative Expense, Total General and Administrative Expense General and administrative Income Statement [Abstract] Debt Instrument, Unamortized Discount, Total Debt Instrument, Unamortized Discount Less: unamortized discount Related and Nonrelated Parties [Domain] Net loss per share, basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Document Period End Date Document Period End Date Payments to Acquire Property, Plant, and Equipment, Total Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Debt Instrument [Line Items] Debt Instrument [Line Items] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted- Average Exercise Price Per Share, Granted Common Stock, Shares Authorized Common stock, shares authorized Statement of Stockholders' Equity [Abstract] Warrants and Rights Outstanding, Measurement Input Warrants and rights outstanding, measurement input Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Other Comprehensive Income (Loss), Net of Tax Comprehensive income (loss) Total other comprehensive gain (loss), net Other comprehensive income (loss) Debt Instrument, Interest Rate, Stated Percentage Debt instrument, interest rate, stated percentage Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options Outstanding Assets Total assets Title of 12(b) Security Title of 12(b) Security Debt Instrument, Frequency of Periodic Payment Debt instrument, frequency of periodic payment Clinical development Accrued Clinical Development Accrued Clinical Development Related Party Transaction [Axis] Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount Contingent payments Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Non-cash Stock-based Compensation Expense Number of Outstanding Options, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Retention stock options issued to purchase common shares Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Variable Rate [Axis] Variable Rate Proceeds from a private placement of common stock and pre-funded warrants, net of issuance costs Proceeds from Issuance of Private Placement Proceeds from a private placement of common stock and pre-funded warrants, net of issuance costs Warrants Not Settleable in Cash, Fair Value Disclosure Fair value of the warrants at the date of issuance Number of trading days Number Of Trading Days Number of trading days Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Options Outstanding Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive gain (loss), net: Year ending December 31, 2024 Debt instrument carrying amount including unaccreted liability for final payment fee maturities repayments of principal in next twelve months. Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Next Twelve Months Increase (Decrease) in Operating Lease Liability Operating lease liabilities Equity, Attributable to Parent Balance Balance Total stockholders' equity Term C Loan. Term C Loan [Member] Term C Loan Entity Address, Address Line Two Entity Address, Address Line Two Other Assets, Noncurrent Other assets Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Income Taxes Income Tax Disclosure [Text Block] Debt prepayment fee as percent from year three. Debt Prepayment Fee As Percent From Year Three Debt prepayment fee as percent from year three Number of Reportable Segments Number of reportable segment Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Long-Term Debt Total Long term loan obligation Credit Facility [Axis] Eighteen months after closing. 18 Months after Closing March Two Thousand Twenty Six Securities Purchase Agreement [Member] March two thousand twenty six securities purchase agreement. March 2026 Purchase Agreement Repayments of Long-Term Debt, Total Repayments of Long-Term Debt Repayment of remaining principal amount and interest outstanding Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Gains Prefunded Warrants Prefunded Warrants [Member] Prefunded Warrants. Proceeds from exercise of stock options Proceeds from Stock Options Exercised Schedule of Future Maturities of Term Loans, Including Final Payment Fee Schedule of Maturities of Long-Term Debt [Table Text Block] Statistical Measurement [Axis] Statistical Measurement Money Market Funds [Member] Money Market Funds Entity Interactive Data Current Entity Interactive Data Current Bioniz therapeutics, inc. Bioniz Therapeutics, Inc. [Member] Bioniz Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Common stock, $0.0001 par value; 400,000,000 and 200,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 63,408,082 and 61,464,368 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively Taxes Payable, Current Taxes Payable, Current, Total Income tax accruals Common Stock Share Available For Sale Common stock sare available for sale. Common stock avaliable to sell Liabilities Total liabilities Ownership [Domain] Pre-BLA CMC projects. Pre-BLA CMC Projects [Member] Pre-BLA CMC Projects Right-of-use assets and lease liabilities, net Increase Decrease In Right-Of-Use Assets And Lease Liabilities, Net Increase (decrease) in right-of-use assets and lease liabilities, net. Business Combination [Text Block] Acquisition Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Retained Earnings (Accumulated Deficit) Accumulated deficit Stephen Connelly Stephen Connelly [Member] Stephen connelly member. Adjustment to additional paid-in capital. Adjustment to additional paid-in capital Adjustment to additional paid-in capital Fair Value, Inputs, Level 3 [Member] Level 3 Common stock reserved for future issuance. Common Stock Reserved For Future Issuance Table [Text Block] Summary of Reserved Shares of Common Stock for Future Issuance Accounts payable Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Operating Expenses Total operating expenses Share Price Closing stock price per share Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Issuance of common stock, Shares Common stock shares issued Issuance of common stock, Shares Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares Business acquisition, common stock shares issued ATM Facility Issuance Costs In Accrued Expenses ATM facility issuance costs in accrued expenses. ATM facility issuance costs in accrued expenses Variable Rate [Domain] Variable Rate Master Services Agreement Master services agreement. Master Services Agreement [Member] Financial liabilities Financial Liabilities Fair Value Disclosure, Total Financial Liabilities Fair Value Disclosure Related Party Transactions [Abstract] Gross proceeds from sale of common stock and warrants Gross Proceeds from Issuance of Common Stock and Warrants Gross proceeds from issuance of common stock and warrants. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of exchange rate changes on cash and cash equivalents Other Income Other (expense) income, net Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV August Two Thound Twenty Five Securities Purchase Agreement [Member] August two thound twenty five securities purchase agreement. August 2025 Purchase Agreement Maturity (in years) Debt Securities, Available-for-Sale, Term Assets, Fair Value Disclosure [Abstract] Additional funding not eligible Line of Credit Facility, Remaining Borrowing Capacity Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Available-for-sale securities Issuance costs Payments of Stock Issuance Costs Research and Development Expense (Excluding Acquired in Process Cost) Research and development Operating Lease, Liability, Current Current portion of operating lease liabilities Lease liabilities, current Business Combination, Recognized Liability Assumed, Liability Total liabilities assumed Total liabilities assumed Liabilities and Equity Total liabilities and stockholders' equity Research and development expense Research and Development Expense, Total Research and Development Expense Document Fiscal Period Focus Document Fiscal Period Focus Proceeds from Issuance of Warrants Proceeds from Issuance of Warrants Sale of Stock [Axis] Sale of Stock Line of credit facility frequency of payments principal and interest. Line Of Credit Facility Frequency Of Payments Principal And Interest Line of credit facility frequency of payments principal and interest Trade Arrangement Expiration Date Trading arrangement expiration date. Expiration Date Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase (decrease) in cash and cash equivalents Entity Current Reporting Status Entity Current Reporting Status Number of Outstanding Options, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Fair Value, Inputs, Level 1 [Member] Level 1 Accounts Payable, Current, Total Accounts Payable, Current Accounts payable Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share Financial Instrument [Axis] Financial Instrument Total assets at fair value Assets, Fair Value Disclosure OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Unrealized loss on available-for-sale securities, net ATM Facility [Member] ATM facility. ATM facility Document Transition Report Document Transition Report Class of Warrant or Right [Axis] Current liabilities: Liabilities, Current [Abstract] Common Stock [Member] Common Stock Business Combination, Recognized Asset Acquired, Asset Total assets acquired Total assets acquired Credit Facility [Domain] Statistical Measurement Statistical Measurement [Domain] Nonoperating Income (Expense) [Abstract] Other income, net: Debt Securities, Available-for-Sale [Line Items] Schedule Of Available For Sale Securities [Line Items] Common stock shares maximum aggregate offering price Common Stock Shares Maximum Aggregate Offering Price Common stock shares maximum aggregate offering price. Equity, Attributable to Parent [Abstract] Stockholders' equity: Weighted-average number of common shares outstanding, basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Assets [Abstract] Assets Entity Central Index Key Entity Central Index Key Non-clinical research Accrued Non-clinical Research. Accrued Non Clinical Research Antidilutive Securities Antidilutive Securities [Axis] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Options Exercisable Stock Issued During Period, Shares, Acquisitions Shares of common stock issued Current Fiscal Year End Date Current Fiscal Year End Date Class of Warrant or Right [Domain] Increase (Decrease) in Accrued Liabilities, Total Increase (Decrease) in Accrued Liabilities Accrued expenses Document Quarterly Report Document Quarterly Report Debt Securities, Available-for-Sale [Table] Debt Securities Available For Sale [Table] Transaction costs Business Combination, Acquisition-Related Cost, Expense Fair Value, Inputs, Level 2 [Member] Level 2 Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Cash Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted- Average Exercise Price Per Share, Ending Balance Weighted- Average Exercise Price Per Share, Beginning Balance Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code State of incorporation Contingent consideration for achievement of regulatory events. Contingent Consideration For Achievement of Regulatory Events [Member] Achievement of Regulatory Events Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Sale of Stock, Number of Shares Issued in Transaction Shares issued and sold Net loss Net loss Ownership [Axis] Exercise Of Stock Options Issuance Costs In Accrued Expenses Exercise of stock options issuance costs in accrued expenses. Exercise of stock option issuance costs in accrued expenses Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet Details Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation gain (loss) Equity Components [Axis] Equity Components Minimum ownership holing percentage Minimum Ownership Holing percentage Minimum ownership holing percentage. Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Investing activities: Partnerships Collaborative Arrangement Disclosure [Text Block] Statement of Cash Flows [Abstract] Loan Agreement. Loan Agreement [Member] Loan Agreement Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Income Tax Disclosure [Abstract] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercise price of repriced options per share Weighted- Average Exercise Price Per Share, Exercised Weighted- Average Exercise Price Per Share, Exercised Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Volume weighted average price per share Volume weighted average price per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities not included in calculation of diluted net loss per share Pre-funded warrants for common stock Pre-Funded Warrants for Common Stock [Member] Pre-Funded warrants for common stock. Measurement Input, Expected Term [Member] Expected Term Number of operating segments Number of Operating Segments Estimated Fair Value Debt Securities, Available-for-sale, Current, Total Debt Securities, Available-for-Sale, Current Short-term investments AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income Awards available under the 2024 Inducement Plan Awards available under 2024 inducement plan. Awards Available Under 2024 Inducement Plan [Member] Deferred revenue Increase (Decrease) in Deferred Revenue Pre-funded warrants issued to purchase warrant shares Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Debt instrument, final payment fees. Debt Instrument Final Payment Fees Debt instrument, final payment fee Weighted- Average Exercise Price Per Share, Forfeitures and Cancellations Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted- Average Exercise Price Per Share, Forfeitures and Cancellations Accrued Liabilities, Current Accrued expenses Total accrued expenses Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Add: accreted liability for final payment fee Accreted liability for final payment fee. Accreted Liability For Final Payment Fee Number of Outstanding Options, Ending Balance Number of Outstanding Options, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Repricing of outstanding options Long-term Debt, Current Maturities, Total Long-Term Debt, Current Maturities Less current portion Short Term Debt [Line Items] Short-Term Debt [Line Items] Short-Term Debt [Table] Schedule Of Short Term Debt [Table] Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Unrealized losses Debt instrument periodic payment terms balloon payment to be paid as percent. Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid As Percent Percentage of final principal payment Document Type Document Type Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Operating activities: Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Notes Payable Mortgage Notes Payable Disclosure [Text Block] Liabilities and Equity [Abstract] Liabilities and stockholders' equity Common Stock Options Stock options issued and outstanding. Stock Options Issued And Outstanding [Member] Stock Options Issued and Outstanding Subsequent Event [Member] Subsequent Event Operating Income (Loss) Loss from operations Measurement Input, Risk Free Interest Rate [Member] Risk Free Rate Sale of Stock, Price Per Share Share price Debt prepayment fee as percent on year one. Debt Prepayment Fee As Percent On Year One Debt prepayment fee as percent on year one Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Employee stock purchase plan. 2018 Employee Stock Purchase Plan Asset Class [Domain] Asset Class Entity File Number Entity File Number Location, Statement of Income, Balance [Axis] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Organization and Significant Accounting Policies Retained Earnings [Member] Accumulated Deficit Expected Dividend Measurement Input, Expected Dividend Rate [Member] Entity Registrant Name Entity Registrant Name Shares, Issued Balance, Shares Balance, Shares Accounting Policies [Abstract] Business Combination, Consideration Transferred, Equity Interest, Type [Axis] Depreciation, Total Depreciation Depreciation Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Entity Address, Address Line One Entity Address, Address Line One Line of Credit Facility, Expiration Date Term Loan maturity date Number of Outstanding Options, Exercised Exercise of stock options, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Business Combination, Recognized Liability Assumed, Liability [Abstract] Liabilities assumed: Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity, Total Net proceeds from the sale of equity Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted- Average Exercise Price Per Share, Exercisable Assets, Current Total current assets Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Business combination recognized identifiable assets acquired and liabilities assumed current liabilities accrued expenses. Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses Accrued expenses Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Supplemental Cash Flow Information [Abstract] Non-cash investing and financing activities: Related Party Transactions Disclosure [Text Block] Related Party Transactions Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) Net liabilities acquired Net liabilities acquired Ownership percentage Sale of Stock, Percentage of Ownership after Transaction Entity Small Business Entity Small Business Long-term Debt, Excluding Current Maturities, Total Long-Term Debt, Excluding Current Maturities Noncurrent portion Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unamortized stock-based compensation expense for stock options Private Placement Issuance Costs In Accounts Payable And Accrued Expenses Private placement issuance costs in accounts payable and accrued expenses. Private placement issuance costs in accounts payable and accrued expenses Long-Term Debt, Type [Axis] Long-term Debt, Type Business Combination, Recognized Asset Acquired, Asset [Abstract] Assets acquired: Debt instrument carrying amount including unaccreted liability for final payment fee. Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Debt instrument carrying amount including unaccreted liability for final payment fee Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued payroll and other employee benefits Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Earnings Per Share [Abstract] Debt prepayment fee as percent on year two. Debt Prepayment Fee As Percent On Year Two Debt prepayment fee as percent on year two Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Stock Option Activity Business combination acquired in-Process research and development Business Combination Acquired in Process Research and Development Acquired in-process research and development Subsequent Event Type [Axis] Equity [Abstract] Expected clinical study costs. Expected Clinical Study Costs Expected clinical study costs Equity [Text Block] Stockholders’ Equity Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Financing activities: Debt instrument, prepayment premium amount. Debt Instrument Prepayment Premium Amount Debt instrument, prepayment fee Entity Incorporation, Date of Incorporation Date of incorporation Biocon and Syngene Biocon and syngene international limited member. Biocon And Syngene International Limited [Member] Accrued Liabilities, Current [Abstract] Non Rule 10B51 Arr Modified Flag Non Rule 10B51 Arr Modified Flag Entity Tax Identification Number Entity Tax Identification Number Debt Instrument, Interest Rate, Basis for Effective Rate Debt instrument, interest rate, basis for effective rate Equity Component [Domain] Equity Component Entity Address, City or Town Entity Address, City or Town Contingent consideration for achievement of commercialization events. Contingent Consideration For Achievement Of Commercialization Events [Member] Achievement of Commercialization Events Business Combination [Axis] Measurement Input Type [Domain] Measurement Input Type Payments to Acquire Short-Term Investments Purchases of short-term investments Amounts included in accounts payable for purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Stock Issued During Period, Value, New Issues Issuance of common stock Accrued expenses related to clinical study costs. Accrued Expenses Related to Clinical Study Costs Accrued expenses related to clinical study costs Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Segment Reporting, Expense Information Used by CODM, Description Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Statement [Table] Statement [Table] Total non-cash stock-based compensation expense Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expense Entity Shell Company Entity Shell Company Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash (used in) provided by investing activities Statement [Line Items] Statement [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets, Total Business Combination, Recognized Asset Acquired, Asset, Noncurrent Fixed assets Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Maximum Maximum [Member] Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current Prepaid expenses and other current assets Debt Disclosure [Abstract] Sale of Stock [Domain] Sale of Stock Required notice period for debt prepayment. Required Notice Period For Debt Prepayment Required notice period for debt prepayment Investment Income, Interest Interest income Business Combination [Domain] Term loan. Term Loan [Member] Term Loan Other income expense net. Other Income Expense Net Total other income, net Debt Issuance Costs, Gross Debt issuance costs ATM facility issuance costs reclassed from other current assets ATM Facility Issuance Costs Reclassed From Other Current Assets ATM facility issuance costs reclassed from other current assets. Consolidation, Policy [Policy Text Block] Principles of Consolidation Payment for Debt Extinguishment or Debt Prepayment Cost Debt instrument, prepayment and termination amount Asset Class [Axis] Asset Class Research and development expense related to clinical study costs. Research and Development Expense Related to Clinical Study Costs Research and development expense related to clinical study costs Assets, Current [Abstract] Current assets: Related Party Transaction [Domain] Line of Credit Line of Credit [Member] Document Fiscal Year Focus Document Fiscal Year Focus Amortization of investments, net Amortization of discount on investments, net Accretion (Amortization) of Discounts and Premiums, Investments Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding Common stock, shares outstanding Prime Rate [Member] Prime Rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Financial Instruments [Domain] Financial Instruments Business Combination [Line Items] ATM Facility At The Market Facility [Member] At the market facility. At The Market Facility Business Combination, Consideration Transferred, Total Business Combination, Consideration Transferred Total consideration Entity Ex Transition Period Entity Ex Transition Period Awards available under 2018 plan. Awards Available Under2018 Plan [Member] Awards Available Under 2018 Equity Incentive Plan Operating Lease, Liability, Noncurrent Long-term operating lease liabilities Lease liabilities, non-current Schedule of Line of Credit Facilities [Table Text Block] Schedule of Aggregate Carrying Amounts of Term Loans Other Accrued Liabilities, Current Other accruals Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock Additional paid-in capital Security Exchange Name Security Exchange Name Measurement Input Type [Axis] Measurement Input Type Related and Nonrelated Parties [Axis] New Accounting Pronouncements, Policy [Policy Text Block] Accounting Pronouncements Pending Adoption Warrant [Member] Common Stock Warrants Warrants for Common Stock Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercisable, per share exercise price Entity Address, State or Province Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average recognition period of stock option unamortized Related Party Transaction, Amounts of Transaction Related party transaction, amount for CMC activities and projects Purchase orders. Purchase Orders Several purchase orders Right-of-use assets Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Business Combination, Contingent Consideration, Type [Axis] Amendment Flag Amendment Flag Terms of merger agreement. Terms Of Merger Agreement Business acquisition, term for finalization after the closing Syngene international limited. Syngene International Limited [Member] Syngene International Limited Debt Instrument [Axis] Debt Instrument City Area Code City Area Code Equillium Inc member. Equillium Inc Member Equillium Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under employee stock purchase plan Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Assets that Require Fair Value Measurements on Recurring Basis and Their Respective Input Levels Based on Fair Value Hierarchy Organization, Consolidation and Presentation of Financial Statements [Abstract] Proceeds from Issuance of Common Stock Gross proceeds from sale of common stock Proceeds from issuance of common stock Operating Expenses [Abstract] Operating expenses: U S Treasury Securities maturing in one year or less. U S Treasury Securities Maturing In One Year Or Less [Member] U.S. Treasury Securities Maturing in One Year or Less Warrant Price Warrant Price Warrant price Common Stock, Par or Stated Value Per Share Common stock, par value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Options Exercisable Liabilities, Current Total current liabilities Business Combination, Contingent Consideration, Type [Domain] Term A Loan. Term A Loan [Member] Term A Loan Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Debt modification, new effective interest rate Debt Modification, New Effective Interest Rate Percentage Debt modification, new effective interest rate percentage. Segment Reporting [Text Block] Segment Reporting Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Net unrealized loss (gain) on foreign currency transactions Net unrealized loss (gain) on foreign currency transactions Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Trading Symbol Trading Symbol Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs related to common stock and pre-funded warrants in a private placement Issuance of common stock and pre-funded warrants in a private placement, net of issuance costs Amortization of term loan discount and issuance costs Amortization of Debt Issuance Costs and Discounts, Total Amortization of Debt Issuance Costs and Discounts Entity Emerging Growth Company Entity Emerging Growth Company Additional Paid-in Capital [Member] Additional Paid-in Capital Long-Term Debt, Gross Principal Project jetFuel merger sub, inc. Project JetFuel Merger Sub, Inc.[Member] Merger Sub Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under employee stock purchase plan, Shares US Treasury Securities [Member] U.S. Treasury Securities Business Combination [Table] Measurement Input, Price Volatility [Member] Volatility Cover [Abstract] Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value Common stock value Issuance of common stock for Bioniz acquisition Long-Term Debt, Type [Domain] Long-term Debt, Type Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated Other Comprehensive Income (Loss), Net of Tax Remainder of 2023 (nine months) Debt instrument carrying amount including unaccreted liability for final payment fee maturities repayments of principal remainder of fiscal year. Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal Remainder Of Fiscal Year Offering cost, expense Offering Cost, Expense Share-based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Maturities of short-term investments 2023 ATM Facility Two thousand twenty three atm facility Two Thousand Twenty Three ATM Facility Member Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Fair Value Disclosures [Abstract] Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalent Cash and cash equivalents Certain Financial Statement Caption Information. Certain Financial Statement Caption Information [Abstract] Employee Stock [Member] Stock Options Employee Stock Purchase Plan Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Business Combination, Recognized Liability Assumed, Accounts Payable, Current Accounts payable Number of Outstanding Options, Forfeitures and Cancellations Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Debt Instrument, Name [Domain] Debt Instrument, Name Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Accounts receivable Increase (Decrease) in Accounts Receivable Other than temporary impairment loss investments available for sale securities Equity Method Investment, Other-than-Temporary Impairment Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Total Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Property and equipment, net Recognized revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Segment Reporting [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Statement of Financial Position [Abstract] Biocon clinical development related to ulcerative colitis study. Biocon Clinical Development Related To Ulcerative Colitis Study Biocon clinical development related to ulcerative colitis study - related party Local Phone Number Local Phone Number